Structure Therapeutics reported cash from operations of -$120.11M and free cash flow of -$155.56M for the quarter ended Jun 2026, down 120.2% year over year. This cash flow statement covers 18 quarters of results from Mar 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||
| Net Income | -13.08M | -13.95M | -12.42M | -11.94M | -17.98M | -23.28M | -23.86M | -5.50M | -26.04M | -26.03M | -33.98M | -10.50M | -46.83M | -61.66M | -65.71M | 59.67M | -75.97M | -106.16M |
| Share-based Compensation | 0.62M | 0.64M | 0.63M | 0.62M | 11.95M | 12.04M | 11.89M | 2.10M | 12.06M | 12.41M | 12.41M | 5.83M | 5.92M | 7.51M | 7.50M | 8.07M | 11.64M | 12.63M |
| Deferred Taxes | -0.01M | -0.12M | ||||||||||||||||
| Cash from Operations | -13.52M | -10.10M | -10.48M | -12.03M | -20.31M | -16.89M | -20.56M | -21.73M | -34.08M | -26.39M | -19.70M | -36.47M | -52.23M | -54.56M | -51.00M | -64.42M | 15.23M | -120.11M |
| Depreciation, Depletion & Amortization | ||||||||||||||||||
| Amortizatization of Intangibles | 0.02M | -0.01M | 0.32M | 0.01M | 0.02M | |||||||||||||
| Change in Working Capital | ||||||||||||||||||
| Change in Account Payables | -1.56M | 1.57M | 2.27M | -0.12M | -0.92M | 1.04M | -2.38M | 1.40M | 1.82M | -4.39M | 6.30M | -0.42M | 0.69M | 0.28M | 8.81M | -5.01M | -4.97M | 3.31M |
| Change in Accured Expenses | 0.54M | 2.49M | -1.54M | 0.06M | -0.56M | 3.48M | 6.09M | 3.15M | -3.03M | 2.18M | 5.55M | 3.02M | -0.99M | 3.60M | 3.88M | 15.02M | -0.13M | 5.51M |
| Other Working Capital Changes | 0.10M | 0.89M | -1.27M | -0.08M | 3.04M | -1.66M | 0.90M | 1.75M | 6.63M | -2.41M | -2.14M | -3.67M | 5.05M | 0.06M | 2.18M | 9.13M | 7.99M | -2.72M |
| Investing Activities | ||||||||||||||||||
| Capital Expenditures | 0.07M | -0.05M | 0.07M | 0.07M | 0.06M | 0.13M | 0.82M | 1.16M | 0.16M | 1.62M | -0.00M | 3.28M | 0.99M | 0.11M | 1.02M | -6.51M | 4.84M | 35.44M |
| Change in Acquisitions & Divestments | 2.00M | 10.50M | 29.40M | 19.60M | 141.08M | -92.78M | 45.88M | 57.00M | 33.50M | 79.50M | 66.40M | 165.50M | 150.45M | 138.00M | 195.92M | 146.17M | 151.70M | 119.09M |
| Cash from Investing Activities | -39.72M | -16.07M | -16.66M | 10.34M | -49.02M | -68.71M | 30.13M | -180.74M | 1.42M | -204.51M | -189.04M | 33.23M | 34.03M | 48.94M | -49.32M | 56.14M | -496.95M | 74.50M |
| Financing Activities | ||||||||||||||||||
| Other financing activities | 0.03M | 172.30M | 127.70M | 0.76M | 0.48M | 0.40M | 0.22M | 0.96M | 0.04M | 0.38M | 92.61M | 0.87M | 1.21M | |||||
| Change in Capital Stock | ||||||||||||||||||
| Net Shares Issued and Repurchased | 4.55M | 5.45M | 2.06M | 4.72M | 0.27M | |||||||||||||
| Net Equity Issued and Repurchased | 57.10M | |||||||||||||||||
| Misc. | ||||||||||||||||||
| Cash from Financing Activities | -1.45M | 31.04M | -0.26M | -0.32M | 169.73M | -0.30M | 0.47M | 281.63M | 0.70M | 514.70M | -0.76M | 0.61M | 0.81M | 0.52M | 56.20M | 704.99M | -1.74M | 2.08M |
| Change in Cash | -54.68M | 4.87M | -27.40M | -2.00M | 100.40M | -85.90M | 10.04M | 79.16M | -31.96M | 283.80M | -209.50M | -2.62M | -17.39M | -5.10M | -44.11M | 696.71M | -483.45M | -43.53M |
| Free Cash Flow | -13.58M | -10.04M | -10.55M | -12.10M | -20.37M | -17.03M | -21.38M | -22.89M | -34.24M | -28.01M | -19.69M | -39.75M | -53.22M | -54.66M | -52.02M | -57.91M | 10.40M | -155.56M |
| Net Cash Flow | -54.68M | 4.87M | -27.40M | -2.00M | 100.40M | -85.90M | 10.04M | 79.16M | -31.96M | 283.80M | -209.50M | -2.62M | -17.39M | -5.10M | -44.11M | 696.71M | -483.45M | -43.53M |